Home > Insider Trading > Filing (0001127602-21-026440)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1145197	Insulet Corp	PODD	Surgical & Medical Instruments & Apparatus (3841)	043523891

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1631895	Shacey Petrovic	C/O Insulet Corporation 100 Nagog Park Acton MA 01720	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-08-31	18,596	$0.00	68,899	No	5	G	Indirect	By NG Trust
Common Stock	Acquisiton	2021-08-31	18,596	$0.00	44,501	No	5	G	Indirect	By SP Trust
Common Stock	Disposition	2021-08-31	38,100	$0.00	6,401	No	5	G	Indirect	By SP Trust
Common Stock	Acquisiton	2021-10-01	7,436	$30.58	23,215	No	4	M	Direct
Common Stock	Acquisiton	2021-10-01	7,564	$29.26	30,779	No	4	M	Direct
Common Stock	Disposition	2021-10-01	15,000	$282.87	15,779	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	G	Indirect	By NG Trust
No	5	G	Indirect	By SP Trust
No	5	G	Indirect	By SP Trust
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2021-10-01	7,436	$0.00	7,436	$30.58
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2021-10-01	7,564	$0.00	7,564	$29.26

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2025-02-09	No	4	M	Direct
37,070		2026-02-24	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.
The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $278.50 to $287.67. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.
This option is subject to a four-year vesting period with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.